Participated · Series B · Mar 2026

Unnatural Products has built an integrated discovery platform to engineer synthetic macrocyclic peptides at scale, combining computational design, automated chemistry, and high-throughput biological testing. The company positions macrocyclic peptides as a modality that can marry biologics-level selectivity with small-molecule delivery properties, including potential oral delivery and cell permeability. Its pipeline targets cardiometabolic, inflammatory, and immunological diseases, and the company is advancing lead programs toward clinical development. Unnatural Products has established collaborations with pharma and biotech partners including Novartis, Merck, BridgeBio and argenx; the Novartis deal includes up to $100 million upfront and up to $1.7 billion in milestones. The recent $45 million Series B will fund further platform development and pipeline advancement. The company is headquartered in Santa Cruz, California.